Google AI
NewsPronto

 

PR Newswire

HEALEY ALS Platform Trial Regimen I expands to 240 participants

  • Written by: PR Newswire Asia - News Pronto RSS

Highlights:

  • Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
  • Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected...

Read more: HEALEY ALS Platform Trial Regimen I expands to 240 participants